Healthcare
A cell and gene therapy accelerator formed by Mayo Clinic, Hibiscus BioVentures and Innoforce is officially up and running, the partners announced this week.
Merck’s bid to buy the cancer-focused Seagen has hit a roadblock after the two companies failed to agree on a price, according to a Bloomberg report.
Despite an anticipated revenue opportunity of $24.48 billion by 2027, a fraction of R&D funding is currently allocated to this space. BioSpace spoke with Organon’s Sandy Milligan about the challenges and progress.
Novartis unveiled plans to separate its generics and biosimilars arm, Sandoz, into a standalone entity, allowing both to pursue independent and more business-appropriate growth strategies.
The Bill & Melinda Gates Foundation inked a memorandum of understanding with South Korea’s foreign and health ministries to expand their partnerships revolving around public health.
Two patients receiving Novartis’ SMA gene therapy Zolgensma have died from acute liver failure, the company reported Thursday.
Healthcare improvement leaders from Concordia University and Premier Inc. say the reasons behind the high cost of healthcare are multifaceted and point out the actual price of innovation.
The FDA will still allow continued distribution of sitagliptin containing NTTP with an acceptable intake limit of 37 ng per day and up to 246.7 ng per day.
Five years after joining Johnson & Johnson as head of research and development, Mathai Mammen is leaving abruptly to seek other opportunities outside the company.
Biogen and others are seeing the value in, particularly, non-prescription digital therapeutics, as complementary companion therapies to disease-modifying drugs.
PRESS RELEASES